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Abstract
Maintenance of normal mineral ion homeostasis is crucial for many biological activities, including proper mineralization of
the skeleton. Parathyroid hormone (PTH), Klotho, and FGF23 have been shown to act as key regulators of serum calcium and
phosphate homeostasis through a complex feedback mechanism. The phenotypes of Fgf23
2/2 and Klotho
2/2 (Kl
2/2) mice
are very similar and include hypercalcemia, hyperphosphatemia, hypervitaminosis D, suppressed PTH levels, and severe
osteomalacia/osteoidosis. We recently reported that complete ablation of PTH from Fgf23
2/2 mice ameliorated the
phenotype in Fgf23
2/2/PTH
2/2 mice by suppressing serum vitamin D and calcium levels. The severe osteomalacia in Fgf23
2/2
mice, however, persisted, suggesting that a different mechanism is responsible for this mineralization defect. In the current
study, we demonstrate that deletion of PTH from Kl
2/2 (Kl
2/2/PTH
2/2 or DKO) micecorrects the abnormal skeletal phenotype.
Bone turnover markers are restored to wild-type levels; and, more importantly, the skeletal mineralization defect is completely
rescued in Kl
2/2/PTH
2/2 mice. Interestingly, the correction of the osteomalacia is accompanied by a reduction in the high
levels of osteopontin (Opn) in bone and serum. Such a reduction in Opn levels could not be observed in Fgf23
2/2/PTH
2/2
mice, and these mice showed sustained osteomalacia. This significant in vivo finding is corroborated by in vitro studies using
calvarial osteoblast cultures that show normalized Opn expression and rescued mineralization in Kl
2/2/PTH
2/2 mice.
Moreover, continuous PTH infusion of Kl
2/2 mice significantly increased Opn levels and osteoid volume, and decreased
trabecular bone volume. In summary, our results demonstrate for the first time that PTH directly impacts the mineralization
disorders and skeletal deformities of Kl
2/2, but not of Fgf23
2/2 mice, possibly by regulating Opn expression. These are
significantnewperceptionsinto the role ofPTHinskeletalanddiseaseprocessesandsuggestFGF23-independentinteractions
of PTH with Klotho.
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Introduction
Maintaining normal mineral ion homeostasis is crucial for
essential biological activities that include but are not limited to
energy metabolism, signaling activities, and normal skeletal growth,
development and function. Blood calcium and phosphate levels are
determined by counterbalance between absorption from the
intestine, mobilization from bone and excretion from the kidney
into urine [1]. This complex process is regulated by several
endocrine factors, including parathyroid hormone (PTH), FGF23
and active Vitamin D, which have been widely studied [2–5]. More
recently, another protein, Klotho, has been suggested to have an
important role in regulating calcium and phosphate homeostasis.
Klotho is a type-I membrane protein mainly expressed in
kidneys, parathyroid glands, and the choroid plexus [6]. It is also
related to b-glucosidases and is found in a soluble form in blood
and cerebrospinal fluid [7,8]. Klotho forms a complex with the
FGF receptor 1c (FGFR1c), thereby converting this canonical
FGF receptor into a receptor specific for FGF23 [9], a negative
regulator of serum phosphate. FGF23 uses the FGFR1c/Klotho
complex to directly target the kidney where it induces phosphate
wasting by decreasing the expression of the sodium-dependent
phosphate co-transporters NaPi2a and NaPi2c [10,11]. Klotho also
regulates serum calcium by affecting both parathyroid gland and
kidney independent of FGF23. When serum calcium is low, Klotho
hydrolyzes extracellular sugar residues on the renal transepithelial
calcium channel TRPV5, entrapping the channel in the plasma
membrane [12]. This maintains continuous calcium channel activity
and membrane calcium permeability, leading to an increase in
tubular reabsorption of calcium in the kidneys and finally increased
serum calcium. In the parathyroid gland, Klotho recruits Na
+/K
+-
ATPase to the cell surface, which results in an increase in PTH
production, which in turn elevates serum calcium level [13,14]. In
addition to Klotho’s independent effect on PTH induction, it can act
togetherwith FGF23 to decreasePTH levels[15,16].An invivo study
has shown that injection of FGF23 protein into rats can lower PTH
secretion and expression [15]. This was confirmed by in vitro
experiments using parathyroid gland cultures [16].
PLoS Genetics | www.plosgenetics.org 1 May 2012 | Volume 8 | Issue 5 | e1002726The function of Klotho as a cofactor of FGF23 was confirmed
in studies by us and others showing that genetic ablation of either
Fgf23 or Klotho results in a similar phenotype [17–19]. Both Klotho
knockout (Kl
2/2) and Fgf23 knockout (Fgf23
2/2) mice exhibit
hypercalcemia, hyperphosphatemia with low to undetectable PTH
levels [20–22], and severe osteomalacia. We have previously
described [23] that deletion of PTH in Fgf23
2/2 mice ameliorated
the abnormal phenotype by normalizing serum Ca
2+ and lowering
serum vitamin D levels, however, the severe osteomalacia persisted
in Fgf23
2/2/PTH
2/2 mice. Because Klotho also has FGF23-
independent functions, we thought it would be important to
investigate the effects of deleting PTH from Kl
2/2 mice. We
demonstrate that the skeletal mineralization defect in Kl
2/2/
PTH
2/2 mice was completely rescued and that this phenomenon
was accompanied by a reduction in the high levels of osteopontin
in bone and serum, a finding that could not be observed in
Fgf23
2/2/PTH
2/2 mice. We also present data showing that
continuous infusion of Kl
2/2 mice with PTH results in an
elevation in OPN levels and subsequently increased osteoid
volume. Our finding demonstrates for the first time that the
skeletal abnormalities and the bone mineralization defect in Kl
2/2
can be rescued by ablation of PTH actions. Our data suggest
regulatory actions on osteopontin by PTH, an important
observation with clinical significance. The identical levels in
serum calcium, phosphate and vitamin D in Fgf23
2/2/PTH
2/2
and Kl
2/2/PTH
2/2 preclude any effects of these parameters on
the regulation of skeletal mineralization and/or Opn levels in these
mice. Additional studies are required to identify the mechanisms
by which PTH affects osteopontin and mineralization in Kl
2/2 but
not in Fgf23
2/2mice.
Results
Deletion of PTH results in healthier Kl
2/2/PTH
2/2 double-
knockout animals
We successfully generated Kl
2/2/PTH
2/2 (DKO) mice by
interbreeding heterozygous Kl
+/2 and PTH
+/2 mice. DKO mice
were more active, healthier and larger in size than Kl
2/2 mice and
more comparable to wild-type and PTH
2/2 single knock-out
littermates (Figure 1A). DKO mice did not show any obvious gross
abnormalities with regard to movement and physical activities,
whereas Kl
2/2 littermates were severely weakened, showing
restricted movement as well as sluggish physical activities. DKO
mouse body weight was significantly higher than that of Kl
2/2
mice (Figure 1B). Compared to the Kl
2/2 mice, DKO mice also
showed a clear improvement in life span as evidenced by a right
shift of the survival curve (Figure 1C). All mice, however, died
before 16 weeks of age, probably due to the severe soft tissue
calcifications such as found in kidney and lung of both Kl
2/2 and
DKO mice (Figure S1).
Serum biochemistry
Six-week old Kl
2/2 and PTH
2/2 mice were severely hypercal-
cemic (10.8660.52 mg/dL) and hypocalcemic (6.8561.17 mg/
dL), respectively. However DKO animals were normocalcemic
(8.7860.42 mg/dL) at 6 weeks, comparable to WT control animals
(9.5260.41 mg/dL), (Figure 2A). Serum phosphate levels in both
Kl
2/2 (14.6160.48 mg/dL) and PTH
2/2 (14.5261.87 mg/dL)
mice were significantly higher compared to those in WT mice
(9.7561.34 mg/dL), (Figure 2B). Interestingly, DKO exhibited a
further increase in serum phosphate to levels (17.6561.86 mg/dL)
far exceeding those in single Kl
2/2 or PTH
2/2 mice. We
determined the total mineral content by calculating the calcium/
phosphate product and found that Kl
2/2 and DKO mice exhibited
similarly high levels (Figure 2C). Measurements of serum
1,25(OH)2D levels showed increased amounts in Kl
2/2 single
knockout mice comparedtothoseinWT and PTH
2/2 mice.Serum
1,25(OH)2D levels in DKO mice were significantly reduced
compared to those of Kl
2/2 single knockout mice, but were still
significantly higher than in wild-type or PTH
2/2 mice (Figure 2D).
We also measured intact serum FGF23 levels and found that DKO
mice had a 50% decrease in serum FGF23 compared to Kl
2/2
mice, however the levels were still significantly higher (1000 fold)
than those in wild-type or PTH
2/2 mice (Figure 2E).
Deletion of PTH rescues skeletal abnormalities of Kl
2/2
mice
We performed peripheral quantitative computerized tomogra-
phy (pQCT) to analyze the bone density in the femurs of all
genotypes. Kl
2/2 mice showed decreased total BMD in the distal
femur metaphysis (Figure 3A). Ablation of the PTH gene from
these mice significantly increased the BMD, which was now
comparable to that of WT and PTH
2/2 mice.
Radiographs showed that the length and radiopacity of the
tibiae from DKO mice were increased and comparable to those of
WT and PTH
2/2 mice (Figure 3B). We performed Alizarin red S
and Alcian blue staining to determine the mineralization pattern
of the bones. As shown in Figure 3C, Kl
2/2 mice exhibited
abnormally widened ribs, but this abnormality could not be
observed in the DKO mice, suggesting an improved skeletal
architecture.
MicroCT (mCT) analysis of the femurs was performed on all
four genotypes. Representative images of distal femoral metaph-
yses and midshaft cortex are shown in Figure 3D and 3E.
Quantification of trabecular bone volume fraction demonstrated
that there is no significant difference between each genotype
(Figure 3F). As mCT can only detect mineralized bone, Kl
2/2 mice
didn’t show increased trabecular volume. However, the midshaft
cortical thickness of the Kl
2/2 mice (0.13260.013 mm) was
significantly reduced compared to the other groups (Figure 3G). It
Author Summary
Maintenance of normal mineral ion homeostasis is crucial
for many biological activities, including proper mineraliza-
tion of the skeleton. PTH, Klotho, and FGF23 are the key
regulators of blood mineral ion homeostasis. Klotho is a
type-I membrane protein and has been identified as
cofactor required for FGF23 to bind and activate its
receptor. Loss of either Klotho or Fgf23 activity results in a
similar abnormal phenotype, including severe defects in
skeletal mineralization and alterations in mineral ion
balance. Here we describe a new mouse model in which
we eliminated PTH from Kl
2/2 mice, and we can show that
the skeletal mineralization defect was completely rescued
in Kl
2/2/PTH
2/2 mice and that this phenomenon was
accompanied by a reduction in the high levels of
osteopontin in bone and serum. We also present
additional data showing that continuous infusion of Kl
2/
2 mice with PTH results in an elevation in Opn levels and
subsequently increased osteoid volume. Interestingly, this
result differs from our previous report in which we
describe that the osteomalacia and the high Opn levels
in Fgf23
2/2/PTH
2/2 mice persisted. Our finding suggests
that PTH, possibly by regulating osteopontin, is responsi-
ble for the skeletal mineralization defect in Kl
2/2 mice, but
not in Fgf23
2/2 mice.
Rescued Osteomalacia and Opn Levels in Kl
2/2 Mice
PLoS Genetics | www.plosgenetics.org 2 May 2012 | Volume 8 | Issue 5 | e1002726Figure 2. Serum biochemical measurement. Abnormal serum calcium levels observed in Kl
2/2 and PTH
2/2 mice were normalized in DKO mice
(A). As for phosphate, DKO mice showed a further increase over already high levels in Kl
2/2 and PTH
2/2 mice (B). Kl
2/2 and DKO mice showed
similarly high CaPi product (C). The serum levels of intact FGF23 (D) and 1,25(OH)2D (E) in DKO mice were partially reduced compared to that of Kl
2/2
mice. *: p,0.05, **: p,0.01, ***: p,0.001vs WT; ###: p,0.001vs Kl
2/2; and $$: p,0.01, $$$: p,0.001 vs DKO.
doi:10.1371/journal.pgen.1002726.g002
Figure 1. Macroscopic phenotype of 6-wk-old mice. (A) Overall phenotype of littermates. Complete deletion of PTH from Kl
2/2 mice resulted in
larger, heavier, and more active DKO mice compared to Kl
2/2 littermates. The body weight of DKO mice is significantly higher than that of Kl
2/2 mice
(B), and the lifespan is slightly improved (C). ###: p,0.001 vs Kl
2/2.
doi:10.1371/journal.pgen.1002726.g001
Rescued Osteomalacia and Opn Levels in Kl
2/2 Mice
PLoS Genetics | www.plosgenetics.org 3 May 2012 | Volume 8 | Issue 5 | e1002726was restored in DKO mice (0.17060.015 mm) to a volume
comparable to that in WT (0.18460.011 mm) and PTH
2/2
(0.18660.016 mm) mice (Figure 3G).
We further analyzed the skeletal properties by generating
undecalcified methylmethacrylate sections from the distal ends of
femurs to confirm the observed improvement in bone mass
compared to Kl
2/2 mice (Figure 4A and 4B). Most importantly,
the severe osteoidosis seen in the secondary spongiosa of Kl
2/2
mice was completely absent in DKO mice (Figure 4B), indicating
the mineralization defect of Kl
2/2 mice was rescued by PTH
ablation. To quantify this observation, we performed histomor-
phometric analyses (Figure 4C–4N). The increased trabecular
bone volume observed in Kl
2/2 mice (18.164.4) was restored in
DKO mice (13.561.9) to values close to those of PTH
2/2 mice
(11.461.6). Interestingly, deletion of PTH also rescued the severe
mineralization defect of Kl
2/2 mice as evidenced by normalized
osteoid volume (OV/TV), osteoid surface (OS/BS) and thickness
(OTh) in DKO mice (Figure 4D–4F). DKO mice also showed
normal trabecular thickness (Tb.Th.), trabecular number (Tb.N.)
and separation (Tb.Sp.), as well as osteoclast surface (Oc.S/BS)
and osteoclast numbers (N.Oc/B.Pm) (Figure 4G–4K). We also
found that the dynamic parameters, including mineral surface
(MS/BS), bone formation rate (BFR/BS) and mineral apposition
rate (MAR) (Figure 4L–4N), were normalized in DKO mice while
the bone labeling in Kl
2/2 mice was unsuccessful due to the severe
mineralization defect.
We next analyzed the concentration of serum markers for
bone turnover. Consistent with histomorphometric data, serum
levels of the carboxyl-terminal telopeptide of type 1 collagen
(CTX), a biomarker of bone resorption activity, were comparable
in DKO (31.5617.2 ng/ml), WT (40.8.5616.2 ng/ml) and
PTH
2/2 (31.563.6 ng/ml) mice (Figure 5A). Similarly, circulat-
ing levels of N-terminal propeptide of type I procollagen (PINP),
a reliable and sensitive marker of bone formation, were
significantly elevated in Kl
2/2 mice (21.866.0 ng/ml)
(Figure 5B). PINP levels were restored in DKO mice
(14.565.0 ng/ml) to levels observed in WT (14.264.6 ng/ml)
and PTH
2/2 (17.061.6 ng/ml).
Figure 3. Rescued skeletal phenotype. Bone Mineral Density (BMD) of distal ends of femurs from 6-week-old mice (A). Radiographs of the tibiae
from all genotypes at 6 wk of age indicate that length and radiopacity of the tibiae were restored in DKO mice (B). Alizarin red S and Alcian blue
staining shows that the abnormally wide ribs in Kl
2/2 mice (indicated by black arrow) were not observed in the DKO mice (C). Representative microCT
images of distal femoral metaphyses (D) and midshaft cortical bone (E) and quantitative analysis (F, G). The midshaft cortical thickness (C.Th) of the
DKO mice was restored to a volume comparable to that of WT and PTH
2/2 mice. ***: p,0.001vs WT; ##: p,0.01, ###: p,0.001 vs Kl
2/2.
doi:10.1371/journal.pgen.1002726.g003
Rescued Osteomalacia and Opn Levels in Kl
2/2 Mice
PLoS Genetics | www.plosgenetics.org 4 May 2012 | Volume 8 | Issue 5 | e1002726Figure 4. Histological and histomorphometric analyses. Undecalcified sections of distal ends of femurs from 6wk-old littermates were stained
with von Kossa and McNeal (A, B). High magnification of the secondary spongiosa shows heavily unmineralized osteoid in Kl
2/2 mice but not in DKO
mice (B). Histomorphometric analysis (C–N) confirmed that the skeletal architecture and mineralization defect of Kl
2/2 mice were rescued in DKO
mice. BV/TV: bone volumes; OV/TV: osteoid volume; OS/BS: osteoid surface/bone surface; OTh; osteoid thickness; Tb.Th: trabecular thickness; Tb.N:
trabecular number; Tb.Sp: trabecular separation; Oc.S/BS: osteoclast surface/bone surface; N.Oc/B.Pm: osteoclast number/bone perimeter; MS/BS:
mineral surface/bone surface; BFR: bone formation rate, and MAR: mineral apposition rate. *: p,0.05, **: p,0.01, ***: p,0.001vs WT; and #: p,0.05,
##: p,0.01, ###: p,0.001 vs Kl
2/2.
doi:10.1371/journal.pgen.1002726.g004
Rescued Osteomalacia and Opn Levels in Kl
2/2 Mice
PLoS Genetics | www.plosgenetics.org 5 May 2012 | Volume 8 | Issue 5 | e1002726Rescued bone mineralization is accompanied by
normalized expression of Opn in DKO mice
To explain the rescue in bone mineralization in DKO mice, we
compared theexpressionofosteopontinand otherfactors associated
with skeletal mineralization in all genotypes. As shown by in situ
hybridization and immunohistochemical staining on decalcified
paraffin sections (Figure 6A and 6B), the expression of Opn, an
inhibitor of osteogenic mineralization and member of the SIBLING
protein family, is abnormally high in the bone. Interestingly, its
expression was normalized in DKO mice to levels seen in WT and
PTH
2/2 mice (Figure 6A and 6B). We also measured serum Opn
levels using an ELISA kit and were able to confirm significantly
elevated serum Opn levels in Kl
2/2 mice, which were restored to
normal levels in DKO mice (Figure 6C). Since we previously
reportedincreasedOpnexpressioninFgf23
2/2bones[17],wewere
interested in also examining their serum Opn levels and found that
they were also significantly increased. In contrast, however, deletion
of PTH from Fgf23
2/2 mice failed to normalize their serum Opn
levels (Figure S2).
To further confirm the in vivo observations in Kl
2/2 and DKO
mice calvarial osteoblasts from 2-day-old littermates were isolated.
Cells were cultured in osteogenic medium for 2 weeks and RNA
was isolated. qPCR analyses showed normal expression of Opn in
osteoblasts of DKO mice (Figure 6D). These osteoblasts also
exhibited normal mineralization as evaluated by Alizarin red
staining while the mineralization of the osteoblasts from Kl
2/2
mice was markedly impaired (Figure 6E). We also evaluated the
expression of Dmp1 and Matrix gla protein (Mgp) by in situ
hybridization and/or qPCR. Both were significantly increased in
Kl
2/2 mice, but rescued in DKO mice (Figure S3).
Infusion of PTH increases Opn levels and led to more
severe mineralization defect
To further investigate the role of Opn in regulating the
mineralization, we perfused PTH (1–34) peptides into the WT and
Kl
2/2 mice using osmotic minipumps. After continuous infusion
for 3 weeks, we observed that the serum Opn levels were
significantly elevated in both WT and Kl
2/2 mice (Figure 7A). As
expected, serum phosphate levels were significantly decreased in
both kinds of mice (Figure S4). PTH infusion, as shown in
Figure 7B–7D, did not change the bone volume in WT mice, but
significantly decreased it in Kl
2/2 mice. More importantly, OV/
BV (Figure 7E) and OS/BS (Figure 7F) of Kl
2/2 mice were further
increased by the PTH infusion, while the mineralized bone
volume (MdV/TV) (Figure 7G) was significantly decreased,
indicating that extraneous PTH induces Opn and thereby worsens
the skeletal mineralization defect in the Kl
2/2 mice. Continuous
PTH infusion also increased osteoblast surface (Ob.S/BS), Oc.S/
BS and N.Oc/B.Pm (Figure 7K–7M) in both WT and Kl
2/2 mice.
Opn contains a RGD sequence, which is important for osteoclast
attachment on the bone. Thus it is not surprising that infusion of
PTH resulted in a significant elevation in serum CTX levels,
indicating increased osteoclastic resorption (Figure 7N). In
addition, PTH infusion significantly elevated serum PINP levels
in both WT and Kl
2/2 mice (Figure 7O).
Discussion
This is the first study using a genetic mouse model with dual
ablation of the Klotho and PTH genes. The results show that
deletion of PTH from Kl
2/2 mice resulted in healthier mice with
normalization of serum calcium levels and complete rescue of the
skeletal phenotype, suggesting that PTH is a crucial contributor to
the skeletal abnormalities caused by loss of Klotho function. More
importantly, we found that deletion of the PTH completely
rescued the mineralization defect in Kl
2/2 mice. Kl
2/2 mice, as
well as Fgf23
2/2 mice, exhibit a severe mineralization defect in
their bones despite excesses in serum calcium and phosphate when
compared to WT mice. The underlying reason for this is largely
unknown but FGF23 is recognized as an inhibitor of mineraliza-
tion. Serum Fgf23 levels in Kl
2/2 mice are two thousand fold
higher than in wild-type littermates. Wang et al [24] show that
adenoviral overexpression of FGF23 in rat calvarial cells inhibits
bone mineralization independent of its systemic effects on
phosphate homeostasis. Our previous report also demonstrated
that FGF23 treatment of primary calvarial osteoblasts from wild-
type mice leads to an inhibition of mineralization [18]. However,
FGF23 requires Klotho for its actions [9,20,25]. In the absence of
Klotho, FGF23 has very low affinity to the FGFR1 and cannot
induce signal transduction (phosphorylation) [9,25,26].
Another intriguing possibility is that Klotho may have a specific
function in osteoblasts associated with PTH. Although Klotho has
been widely accepted as the cofactor of FGF23 signaling [9,26,27],
and Kl
2/2 and Fgf23
2/2 mice share very similar phenotypes [20],
we show here that deletion of PTH fully rescues the mineralization
defect in Kl
2/2 mice, but could not improve this defect in Fgf23
2/
2 animals [23]. More recently, Klotho has been reported to be
expressed in the osteoblastic cell linage [28]. In addition, previous
studies have shown that Klotho does exert endogenous actions in
calcium homeostasis and control of PTH secretion [13,14] that are
independent of FGF23. Similarly, Klotho directly mediates
secretion of PTH through recruitment of Na
+/K
+ ATPase to
the plasma membrane [14]. Recent studies also showed that Kl
2/2
mice have increased trabecular bone [29,30]. In this study, we
confirmed elevated bone volume in Kl
2/2 mice compared to the
Figure 5. Measurement of serum CTX and PINP. Measurement of serum CTX (A) and PINP (B), indicating normalized bone turnover in DKO mice.
*: p,0.05, **: p,0.01vs WT; ##: p,0.01vs Kl
2/2.
doi:10.1371/journal.pgen.1002726.g005
Rescued Osteomalacia and Opn Levels in Kl
2/2 Mice
PLoS Genetics | www.plosgenetics.org 6 May 2012 | Volume 8 | Issue 5 | e1002726normal bone volume in Fgf23
2/2 mice. More importantly,
cultured osteoblasts isolated from Kl
2/2 pups at the age of 2-
days showed markedly impaired mineralization, suggesting that
Klotho may play a specific role in osteoblasts. Moreover, we
detected low Klotho expression by qPCR in both cultured
osteoblasts and isolated cortical bone (Figure S5). An osteoblast-
specific Klotho knockout mouse model may be required to dissect
the role of Klotho during skeletogenesis.
To examine the bone mineralization defect in more detail, we
determined the expression of Opn by in situ hybridization,
immunohistochemistry, ELISA and quantitative PCR. Opn is a
well-known mineralization inhibitor, and mice deficient in Opn
show soft tissue calcification and premature bone mineralization
[31,32]. Our analyses showed that the increased amount of Opn
detected in Kl
2/2 mice was normalized in DKO mice. PTH is
known to be an important regulator of Opn and can induce the
expression of Opn in MC3T3-E1 cells within 3 hours [33,34].
Therefore, the complete ablation of PTH might be responsible for
the normalization of the increased Opn levels in Kl
2/2 mice and
subsequently rescue the mineralization defect. Furthermore,
infusion of exogenous PTH into Kl
2/2 mice resulted in a
significant elevation in Opn levels with a worsened mineralization
defect. This further strengthens our hypothesis that PTH could
regulate skeletal mineralization in Kl
2/2 mice via Opn.
Although studies suggest that phosphate could also regulate the
expression of Opn [35–37], our previous study using Fgf23
2/2/
NaPi2a
2/2 mice suggested that the elevated expression of Opn in
bones of Fgf23
2/2 mice is at least partially independent of systemic
phosphate levels [18]. This was further supported by our
observation in this study that PTH
2/2 and DKO mice had normal
expression of Opn despite very high serum phosphate levels. In
addition, we also found in this study that PTH infusion could
increase the serum Opn, even while the serum phosphate levels
were decreased (Figure S4). Moreover, serum calcium, phosphate
Figure 6. Normalized expression of Opn in DKO mice. In situ hybridization (A) and immunohistochemical staining (B) on paraffin sections
prepared from tibiae of animals at 6 weeks of age. The elevated Opn expression in Kl
2/2 mice was normalized in DKO mice. (C) Measurements of the
serum Opn levels. Quantitive PCR confirmed the normal expression of Opn in the osteoblasts isolated from DKO mice (D). DKO osteoblasts also
exhibited normal mineralization as evaluated by Alizarin red staining (E). *: p,0.05, ***: p,0.001vs WT; and #: p,0.05, ###: p,0.001 vs Kl
2/2.
doi:10.1371/journal.pgen.1002726.g006
Rescued Osteomalacia and Opn Levels in Kl
2/2 Mice
PLoS Genetics | www.plosgenetics.org 7 May 2012 | Volume 8 | Issue 5 | e1002726Figure 7. Infusion of PTH increases Opn levels and leads to a more severe mineralization defect. PTH infusion increased serum Opn
levels (A). Undecalcified sections of distal ends of femurs were stained with von Kossa and McNeal (B, C). Histomorphometric analysis (D–M) showed
that PTH infusion decreased the bone volume (BV/TV) and increased osteoid volume (OV/BV) in Kl
2/2 mice. Serum CTX (N) and PINP (O) levels were
significantly increased after PTH infusion. MdV/TV: mineralized bone volume/total volume. Ob.S/BS: osteoblast surface/bone surface. *: p,0.05, **:
p,0.01, ***: p,0.001vs vehicle controls.
doi:10.1371/journal.pgen.1002726.g007
Rescued Osteomalacia and Opn Levels in Kl
2/2 Mice
PLoS Genetics | www.plosgenetics.org 8 May 2012 | Volume 8 | Issue 5 | e1002726and vitamin D levels in Fgf23
2/2/PTH
2/2 and Kl
2/2/PTH
2/2
are identical and can therefore not contribute to the regulation of
skeletal mineralization and/or Opn levels in these mice.
In summary, the findings in this study demonstrate that genetic
ablation of PTH resulted in healthier DKO mice. More
importantly, deletion of PTH completely rescued the skeletal
abnormalities, including the severe mineralization defect in Kl
2/2
mice, and this effect is very likely associated with normalized
expression of Opn in DKO mice. Interestingly, we previously
showed that deletion of PTH in Fgf23
2/2 mice could not rescue
mineralization, implying an independent function of Klotho in
bone. This study demonstrates that the activity of the low level of
PTH remaining in Kl
2/2 mice contributes to the severe
mineralization disorder and skeletal abnormalities caused by the
loss of Klotho function. Moreover, we show that Klotho affects
mineralization independently of its role as a co-factor for FGF23.
Further analyses are needed to determine the independent roles
of PTH and Klotho in mineral ion homeostasis and skeletal
mineralization and their detailed molecular interactions, includ-
ing those involving OPN.
Materials and Methods
Animals
Heterozygous- Kl
+/2 and PTH
+/2 animals were interbred to
attain wild-type (WT), Kl
2/2, Kl
2/2/PTH
2/2 (double knockout,
DKO) and PTH
2/2 animals for subsequent analyses. Routine PCR
was used to genotype various mice as described previously [20,38].
The total body weight of each mouse was measured weekly
starting at 3 weeks after birth. All studies performed were
approved by the Institutional Animal Care and Use Committee
at the Harvard Medical School.
Biochemical analyses
Blood was obtained by puncturing the cheek pouch of animals.
Total serum calcium and phosphorus levels were determined
using Stanbio LiquiColor (Arsenazo III) and LiquiUV kits
(Stanbio Laboratory, Boerne, TX), respectively. Serum concen-
trations of FGF23 and Opn were measured using commercial
kits from Kainos Laboratories, Inc., (Tokyo, Japan), and R&D
Systems, Inc. (Minneapolis, MN), respectively. The ELISA kits
for 1,25(OH)2D, PINP and CTX were purchased from IDS
(Fountain Hills, AZ).
Skeletal mineralization and bone mineral density
The mineralization pattern of the skeleton was analyzed by
Alizarin red S and Alcian blue staining in 6- week-old mice, as
described by McLeod [39]. Femurs of all genotypes at 6 weeks of
age were flushed and exposed to X-ray (20 kV, 5 seconds). As
described previously [40], bone mineral density (BMD) and mCT
analysis were performed by peripheral quantitative computerized
tomography (pQCT) and by using a Scanco Medical mCT 35
system (Scanco), respectively.
Bone histology and histomorphometry
Processing of undecalcified bone specimens and cancellous bone
histomorphometry in the distal femoral metaphysis were per-
formed as described [40]. The area within 0.25 mm from the
growth plate was excluded from the measurements.
Soft tissue calcifications
Von Kossa staining was performed using 5 mm paraffin sections
of kidneys and lungs isolated from 9-week-old animals.
In situ hybridization
Complementary
35S-UTP-labeled riboprobe osteopontin (Opn)
and dentin matrix protein 1 (Dmp1) were used for performing in
situ hybridization on paraffin sections, as described previously
[41].
Immunohistochemistry
Immunohistochemistry was performed using mouse Opn
antibody (R&D, Minneapolis, MN) with a working concentration
of 0.5 mg/ml overnight at 4uC. Tissue was stained with anti-goat
HRP substrate and DAB (Vector, Burlingame, CA), and then
counterstained with hematoxylin.
Mouse calvarial cell culture
Mouse calvarial cell culture was carried out as previously
described [18]. Cells were treated with 50 mg/ml ascorbic acid
and 10 mM b-glycerophosphate (bGP) to induce matrix miner-
alization. Total RNA isolation and Alizarin red S staining were
performed 14 days after induction.
Quantitative real-time PCR
Total RNA was from cultured osteoblasts using Trizol reagents
(Invitrogen) according to the manufacturer’s protocol. For qRT-
PCR, cDNA was prepared using QuantiTec reverse transcription
kit (Qiagen) and analyzed with SYBR GreenMaster Mix
(SABiosciences) in the iCycler (Bio-Rad) using specific primers
designed for each targeted gene. Relative expression was
calculated using the 2
2DDCt method by normalizing with Gapdh
housekeeping gene expression, and presented as fold increase
relative to control.
In vivo continuous PTH (1–34) infusion
50 mg per kilogram of body weight per day of human PTH 1–34
(Polypeptide Group, France) were delivered into 3-week-old
animals for a 3-week period using implanted ALZET osmotic
minipumps, Model-1004 (DURECT Corporation, Cupertino,
CA). Animals of vehicle group were infused with an equal volume
of sterile saline.
Statistics
Statistically significant differences between groups were evalu-
ated by Student’s t-test for comparison between two groups or by
one-way analysis of variance (ANOVA) followed by Tukey’s test
for multiple comparisons. And those between vehicle and PTH-
infused groups were evaluated by Student’s t-test. All values were
expressed as mean 6 SD. A p value of less than 0.05 was
considered to be statistically significant.
Supporting Information
Figure S1 Von Kossa staining of kidney sections (A) and lung
sections (B) isolated from 9-week-old animals. Soft tissue
calcification was observed in both Kl
2/2 and Klotho/PTH double
knockout (DKO) mice.
(TIF)
Figure S2 Serum osteopontin (Opn) levels in (A) wild-type (WT)
and Fgf23
2/2 mice at 3 and 6 weeks of age. (B) Comparison of
serum Opn levels between WT, Fgf23
2/2, Fgf23
2/2/PTH
2/2
(DKO), and PTH
2/2 mice at 6 weeks. ***: p,0.001vs vehicle
controls, ###: p,0.001 vs Fgf23
2/2, $$$: p,0.001 vs DKO.
(TIF)
Figure S3 Gene expression of Dmp1 and Mgp. (A) in situ
hybridization of bone sections showed that Dmp1 expression was
Rescued Osteomalacia and Opn Levels in Kl
2/2 Mice
PLoS Genetics | www.plosgenetics.org 9 May 2012 | Volume 8 | Issue 5 | e1002726elevated in Kl
2/2 mice. (B and C) mRNA expression of Dmp1 and
Mgp in osteoblasts was quantified by qPCR analysis. Calvarial
osteoblasts were isolated and cultured in osteogenic medium for 2
weeks. *: p,0.05, **: p,0.01 vs WT; ##: p,0.01 vs Kl
2/2.
(TIF)
Figure S4 Serum phosphate measurements. PTH infusion
significantly decreased serum phosphate levels in both WT and
Kl
2/2 animals. **: p,0.01, ***: p,0.001vs vehicle controls.
(TIF)
Figure S5 Gene expression of Klotho in bone and osteoblasts
quantified by qPCR. Klotho expression was detected in the both
cultured osteoblasts and cortical bones. However, it was much
lower than that observed in the kidney. Tissues from Kl
2/2 mice
were used as negative controls. ***: p,0.001.
(TIF)
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